海尔生物
(688139)
| 流通市值：99.25亿 | | | 总市值：99.25亿 |
| 流通股本：3.16亿 | | | 总股本：3.16亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,296,472,460.72 | 652,078,594.24 | 2,328,672,376.01 | 1,761,188,311.04 |
| 营业收入 | 1,296,472,460.72 | 652,078,594.24 | 2,328,672,376.01 | 1,761,188,311.04 |
| 二、营业总成本 | 1,168,979,905.85 | 581,544,373.93 | 2,111,350,181.83 | 1,585,741,477.6 |
| 营业成本 | 685,462,902.24 | 342,016,271.67 | 1,239,105,142.69 | 942,056,612.63 |
| 税金及附加 | 10,980,541.94 | 5,976,918.91 | 22,653,316.45 | 17,541,367.95 |
| 销售费用 | 206,805,718.71 | 98,873,526.27 | 359,420,983.07 | 261,326,293.36 |
| 管理费用 | 95,535,365.3 | 48,191,207.24 | 192,799,698.62 | 144,351,857.08 |
| 研发费用 | 172,497,422.42 | 83,989,527.35 | 323,249,127.18 | 242,638,381.62 |
| 财务费用 | -2,302,044.76 | 2,496,922.49 | -25,878,086.18 | -22,173,035.04 |
| 其中:利息费用 | 1,825,535.7 | 883,959.2 | 3,909,387.58 | 2,870,080.47 |
| 其中:利息收入 | 16,396,216.38 | 8,762,595.23 | 35,370,669.84 | 25,163,808.59 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,224,070.28 | 496,729.71 | -494,110.38 | 2,021,962.32 |
| 加:投资收益 | 5,829,691.33 | 2,606,333.76 | 27,308,983.33 | 21,375,762.75 |
| 资产处置收益 | -102,532.28 | 88.5 | 632,148.71 | 186,508.98 |
| 资产减值损失(新) | -2,239,082.03 | 206,036.98 | -8,507,764.46 | -3,749,191.32 |
| 信用减值损失(新) | 963,879.07 | -6,844,353.25 | -12,795,863.25 | -14,374,998.15 |
| 其他收益 | 20,924,068.54 | 16,933,387.63 | 42,877,805.34 | 30,932,247.14 |
| 四、营业利润 | 155,092,649.78 | 83,932,443.64 | 266,343,393.47 | 211,839,125.16 |
| 加:营业外收入 | 2,183,527.9 | 1,235,935.33 | 2,064,888.6 | 975,898.12 |
| 减:营业外支出 | 811,741.82 | 561,951.32 | 3,648,309.24 | 2,630,049.89 |
| 五、利润总额 | 156,464,435.86 | 84,606,427.65 | 264,759,972.83 | 210,184,973.39 |
| 减:所得税费用 | 7,548,899.06 | 4,617,102.32 | 9,627,692.26 | 8,045,481.34 |
| 六、净利润 | 148,915,536.8 | 79,989,325.33 | 255,132,280.57 | 202,139,492.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 148,915,536.8 | 79,989,325.33 | 255,132,280.57 | 202,139,492.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 147,414,556.88 | 79,460,846.19 | 250,730,796.6 | 198,390,896.36 |
| 少数股东损益 | 1,500,979.92 | 528,479.14 | 4,401,483.97 | 3,748,595.69 |
| 扣除非经常损益后的净利润 | 137,547,657.29 | 70,673,678.49 | 219,650,111.67 | 173,473,083.52 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.47 | 0.25 | 0.8 | 0.63 |
| (二)稀释每股收益 | 0.47 | 0.25 | 0.8 | 0.63 |
| 八、其他综合收益 | -4,460,748.4 | -9,068.24 | 10,148,619.24 | 297,407.11 |
| 归属于母公司股东的其他综合收益 | -4,460,748.4 | -9,068.24 | 10,148,619.24 | 297,407.11 |
| 九、综合收益总额 | 144,454,788.4 | 79,980,257.09 | 265,280,899.81 | 202,436,899.16 |
| 归属于母公司股东的综合收益总额 | 142,953,808.48 | 79,451,777.95 | 260,879,415.84 | 198,688,303.47 |
| 归属于少数股东的综合收益总额 | 1,500,979.92 | 528,479.14 | 4,401,483.97 | 3,748,595.69 |
| 公告日期 | 2026-08-20 | 2026-04-30 | 2026-03-28 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |